Status:
RECRUITING
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Lead Sponsor:
University Hospital Schleswig-Holstein
Collaborating Sponsors:
UCB Biopharma SRL
University of Kiel
Conditions:
Parkinson Disease
Eligibility:
All Genders
50-99 years
Brief Summary
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort lon...
Detailed Description
The PASS-PP Study is designed to combine the latest developments in clinical and biomarker research to 1. understand the distribution of risk profiles for PD in the general population, especially reg...
Eligibility Criteria
Inclusion
- Age between 50 and 99
Exclusion
- Presence of clinical PD at the time of study inclusion
- Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
- other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
- in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04724941
Start Date
June 1 2021
End Date
December 1 2027
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department for Neurology, University of Kiel
Kiel, Germany, 24118